A Chinese medicine composition for treating bronchiectasis and its preparation method

Abstract

The present invention relates to the technical field of traditional Chinese medicine, and discloses a traditional Chinese medicine composition for treating bronchiectasis and a preparation method thereof. The traditional Chinese medicine composition is prepared from the following traditional Chinese medicine raw materials in parts by weight: 3-30 parts of reed rhizome, 3-30 parts of raw astragalus root, 3-30 parts of codonopsis pilosula, 3-30 parts of ophiopogon japonicus, 3-15 parts of roasted licorice root, 3-30 parts of raw coix seed, 3-30 parts of wax gourd seed, 3-15 parts of peach kernel, 3-10 parts of pinellia tuber, 3-20 parts of platycodon grandiflorum, 3-20 parts of aster root, and 3-10 parts of polygala tenuifolia. The traditional Chinese medicine composition provided by the present invention can significantly reduce the number of acute exacerbations in patients with stable bronchiectasis in a state of high airway mucus secretion; improve the patients' traditional Chinese medicine symptoms and cough and sputum symptoms, thereby improving the patients' quality of life; and can partially improve the patients' lung function, and at the same time, there is a trend of reducing the levels of serum inflammatory factors and proteases in patients with bronchiectasis.

Description

Technical Field

[0001] The present invention relates to the field of traditional Chinese medicine, and in particular to a traditional Chinese medicine composition for treating bronchiectasis and a preparation method thereof. Background Art

[0002] Chronic inflammation of the airway mucosa in patients with bronchiectasis leads to mucus hypersecretion, which reduces the clearance and expectoration abilities of cilia. This leads to long-term accumulation of mucus in the airways, bacterial proliferation, and recurrent coughing and expectoration, which in turn causes repeated acute exacerbations of bronchiectasis. Therefore, improving airway mucus hypersecretion is an important component of long-term treatment for patients with bronchiectasis and a key factor in preventing repeated acute exacerbations.

[0003] Currently, bronchiectasis treatment focuses on anti-infection in the acute phase and symptom improvement during remission. Expectorant therapy is the primary treatment for airway mucus hypersecretion, with postural drainage and expectoration being a key component of conventional treatment. Expectorant therapy for patients with chronic airway inflammatory diseases helps prevent recurrent infections and slow the decline in lung function. It has become a crucial component of the treatment of chronic airway inflammatory diseases, particularly bronchiectasis characterized by copious amounts of purulent sputum.

[0004] However, it should be noted that neither mucolytics nor mucomodulators have a significant effect on reducing airway mucus secretion, which is a major issue currently facing the treatment of airway mucus hypersecretion. Summary of the Invention

[0005] The purpose of the present invention is to provide a traditional Chinese medicine composition for treating bronchiectasis, which can improve the hypersecretion of airway mucus and reduce the frequency of acute exacerbations of bronchiectasis.

[0006] Another object of the present invention is to provide a method for preparing the above-mentioned traditional Chinese medicine composition for treating bronchiectasis.

[0007] To solve the above technical problems, the first aspect of the present invention provides a traditional Chinese medicine composition for treating bronchiectasis, which is prepared from the following traditional Chinese medicine raw materials in parts by weight: 3-30 parts of reed rhizome, 3-30 parts of raw astragalus, 3-30 parts of codonopsis pilosula, 3-30 parts of ophiopogon, 3-15 parts of roasted licorice, 3-30 parts of raw coix seed, 3-30 parts of wax gourd seed, 3-15 parts of peach kernel, 3-10 parts of pinellia, 3-20 parts of platycodon, 3-20 parts of aster, and 3-10 parts of polygala.

[0008] Preferably, the traditional Chinese medicine composition for treating bronchiectasis provided by the present invention is prepared from the following traditional Chinese medicine raw materials in parts by weight: 30 parts of reed rhizome, 30 parts of raw astragalus, 10 parts of codonopsis pilosula, 20 parts of ophiopogon japonicus, 10 parts of roasted licorice root, 20 parts of raw coix seed, 15 parts of wax gourd seed, 10 parts of peach kernel, 10 parts of pinellia, 12 parts of platycodon, 15 parts of aster, and 10 parts of polygala.

[0009] The second aspect of the present invention provides a method for preparing a Chinese medicine composition for treating bronchiectasis, comprising the following steps: (1) weighing the following Chinese medicine raw materials in parts by weight: 3-30 parts of Phragmites australis, 3-30 parts of raw Astragalus membranaceus, 3-30 parts of Codonopsis pilosula, 3-30 parts of Ophiopogon japonicus, 3-15 parts of roasted Licorice root, 3-30 parts of raw Coix seeds, 3-30 parts of Wax gourd seeds, 3-15 parts of peach kernels, 3-10 parts of Pinellia ternata, 3-20 parts of Platycodon grandiflorum, 3-20 parts of Aster tataricus, and 3-10 parts of Polygala tenuifolia; (2) mixing the Chinese medicine raw materials, extracting them with a solvent, obtaining an extract, and further preparing the extract into a desired dosage form; or extracting the Chinese medicine raw materials with a solvent separately, obtaining the extract into a desired dosage form, and then mixing the mixture.

[0010] Preferably, in the method for preparing the traditional Chinese medicine composition for treating bronchiectasis provided by the present invention, the extraction method adopted in the solvent extraction is water decoction extraction or alcohol solution extraction.

[0011] Preferably, the method for preparing the Chinese medicine composition for treating bronchiectasis provided by the present invention further comprises preparing the Chinese medicine composition into a conventional dosage form using a conventional Chinese medicine preparation method.

[0012] More preferably, in the present invention, the Chinese medicine composition is prepared into granules, decoctions, tablets, capsules or pills.

[0013] Registered clinical studies on Traditional Chinese Medicine (TCM) treatments for airway mucus hypersecretion in stable bronchiectasis are still lacking. TCM's extensive phlegm-reducing methods should not only "thin out" mucus, but also focus on eradicating mucus production. Therefore, improving airway mucus hypersecretion through TCM treatments and thereby reducing the frequency of acute exacerbations of bronchiectasis is a crucial topic.

[0014] Compared with the prior art, the Chinese medicine composition of the present invention has the following characteristics in the selection of raw materials and medicinal flavors: the formula mainly uses reed root, which is sweet, cold and light, and clears lung heat as the main ingredient; Codonopsis pilosula is mild in nature and flavor, can replenish the qi of the lungs and spleen, and promote the production of body fluids. "Compendium of Materia Medica" says that it "tonifies the middle qi, harmonizes the spleen and stomach, and eliminates thirst. It is very safe to use it to regulate and replenish the middle qi when it is slightly deficient"; Ophiopogon japonicus is good at nourishing yin and moistening dryness, and its combination of clearing and moistening can increase water flow and promote the discharge of phlegm; Raw Astragalus membranaceus nourishes the lungs and strengthens the spleen and stomach. The spleen is sweet and warm, dispelling heat and promoting the expulsion of pus and toxins. Roasted licorice root, with its sweet and warm properties, clears heat and tonifies the spleen and stomach's vital energy. Winter melon seeds clear heat and dampness, and when used with peach kernels, they dissipate blood stasis and resolve turbidity, encouraging the expulsion of phlegm and heat through the stool. Raw coix seeds clear phlegm and heat, dissipate dampness and expel pus. Pinellia tuber, a decoction for dispelling turbidity and relieving qi, works with Ophiopogon japonicus to simultaneously moisten and dry dampness, inhibiting mucus hypersecretion in the epithelial airways. Aster tataricus, Platycodon grandiflorum, and Polygala tenuifolia inhibit the expression of MUC5AC mRNA in airway epithelial cells, improving mucociliary clearance and reducing sputum. This formula, carefully formulated to balance the effects of strengthening the body's resistance, dispelling pathogenic factors, clearing the lungs and resolving phlegm, and invigorating qi and yin. Therefore, it is effective in treating stable bronchiectasis, offering convenient administration, low dosage, and long-term use without toxic side effects.

[0015] In terms of pharmacodynamics, preliminary clinical studies (such as prospective randomized clinical studies or case-control clinical studies) have demonstrated that the Chinese medicine composition provided by the present invention not only effectively reduces the frequency of acute exacerbations of bronchiectasis but also significantly improves airway mucus hypersecretion in bronchiectasis patients, demonstrating a significant therapeutic effect on bronchiectasis patients. Furthermore, further clinical trials have demonstrated that the Chinese medicine composition provided by the present invention is efficacious in treating bronchiectasis, with no drug-induced side effects observed in the clinical trials. The composition is a safe and effective drug for the treatment of bronchiectasis.

[0016] The applicant conducted a prospective comparative case study, recording the number of acute exacerbations, cough and sputum assessment questionnaire scores, and traditional Chinese medicine symptom scores during the medication period and the medication follow-up period. Furthermore, the applicant used an enzyme-linked immunosorbent assay (ELISA) to detect inflammatory factors in the serum before and after treatment with the traditional Chinese medicine composition of the present invention. This study demonstrated that the traditional Chinese medicine composition provided by the present invention can effectively reduce the hypersecretion of airway mucus in patients with bronchiectasis and effectively reduce some inflammatory factors. Furthermore, the raw materials involved in the present invention are all natural Chinese herbal medicines, all of which are included in the Chinese Pharmacopoeia (2000 edition) Volume 1 and meet the pharmacopoeia quality requirements. They are easy to obtain, simple to prepare, have a wide source of medicine, and are low in cost. DETAILED DESCRIPTION

[0017] To make the objectives, technical solutions, and advantages of the present invention more clearly apparent, various embodiments of the present invention will be described in detail below. However, those skilled in the art will appreciate that, in various embodiments of the present invention, many technical details are provided to help readers better understand the present application. However, even without these technical details and various variations and modifications based on the following embodiments, the technical solutions claimed in the present application can still be implemented.

[0018] Chinese medicine composition

[0019] In a first aspect, an embodiment of the present invention provides a traditional Chinese medicine composition for treating bronchiectasis, which is prepared from the following traditional Chinese medicine raw materials in parts by weight: 3-30 parts of reed rhizome, 3-30 parts of raw astragalus, 3-30 parts of codonopsis pilosula, 3-30 parts of ophiopogon, 3-15 parts of roasted licorice, 3-30 parts of raw coix seed, 3-30 parts of wax gourd seed, 3-15 parts of peach kernel, 3-10 parts of pinellia, 3-20 parts of platycodon, 3-20 parts of aster, and 3-10 parts of polygala.

[0020] In some embodiments of the present invention, the traditional Chinese medicine composition for treating bronchiectasis is made from the following traditional Chinese medicine raw materials in parts by weight: 30 parts of reed rhizome, 30 parts of raw astragalus, 10 parts of codonopsis pilosula, 20 parts of ophiopogon japonicus, 10 parts of roasted licorice root, 20 parts of raw coix seed, 15 parts of wax gourd seed, 10 parts of peach kernel, 10 parts of pinellia, 12 parts of platycodon, 15 parts of aster, and 10 parts of polygala.

[0021] Preparation of Chinese medicine composition

[0022] In a second aspect, an embodiment of the present invention provides a method for preparing the Chinese medicine composition of the first aspect of the present invention:

[0023] (1) Weigh the following Chinese medicinal raw materials in parts by weight: 3-30 parts of Phragmites australis, 3-30 parts of raw Astragalus, 3-30 parts of Codonopsis pilosula, 3-30 parts of Radix Ophiopogonis, 3-15 parts of Radix Glycyrrhizae, 3-30 parts of raw Coix seeds, 3-30 parts of Wax Gourd seeds, 3-15 parts of Peach kernels, 3-10 parts of Pinellia, 3-20 parts of Platycodon, 3-20 parts of Aster, and 3-10 parts of Polygala; (2) Mix the Chinese medicinal raw materials, extract them with a solvent, and prepare the extract into a desired dosage form; or extract the Chinese medicinal raw materials separately with a solvent, prepare the extract into the desired dosage form, and then mix them.

[0024] In some embodiments of the present invention, the extraction method adopted in the solvent extraction is water decoction extraction or alcohol solution extraction.

[0025] In some embodiments of the present invention, in the step of preparing the desired dosage form, the traditional Chinese medicine composition is prepared into a conventional dosage form using conventional traditional Chinese medicine preparation methods.

[0026] In some embodiments of the present invention, the traditional Chinese medicine composition is prepared into granules, decoctions, tablets, capsules or pills.

[0027] The advantages of the present application are further illustrated below in conjunction with the examples of the present invention. It should be understood that the examples are only used to illustrate the present application and are not used to limit the scope of the present application.

[0028] Example 1 Preparation of the Chinese herbal compound preparation granules of the present invention (Qingbu Weijing Decoction Granules)

[0029] (1) Weigh the following Chinese medicinal materials in parts by weight: 30 parts of Phragmites australis, 30 parts of raw Astragalus root, 10 parts of Codonopsis pilosula, 20 parts of Ophiopogon japonicus, 10 parts of roasted Licorice root, 20 parts of raw Coix seed, 15 parts of Wax gourd seed, 10 parts of Peach kernel, 10 parts of Pinellia ternata, 12 parts of Platycodon grandiflorum, 15 parts of Aster tataricus, and 10 parts of Polygala tenuifolia.

[0030] (2) According to the solvent amount, temperature and holding time of each Chinese medicine raw material, extract each Chinese medicine raw material symmetrically, separate the residue, concentrate, dry, crush and sieve to make the extract powder of each Chinese medicine raw material, and then mix and dry granulate to obtain the granules of the Chinese medicine composition. Test Example 1 Clinical Prediction Index Change Study

[0031] 1. Case selection method

[0032] This study collected a total of 80 patients with stable bronchiectasis who met the inclusion criteria, including 40 cases in the control group and 40 cases in the observation group. The research subjects were outpatients and inpatients from the Department of Pulmonary Diseases, Xiyuan Hospital, China Academy of Chinese Medical Sciences who met the inclusion criteria.

[0033] 1.1 Inclusion criteria

[0034] (1) Patients who meet the diagnostic criteria for bronchiectasis; (2) Patients who have not smoked in the past year before enrollment, have sputum volume >30ml per day, and have no acute exacerbation found in history collection and physical examination; (3) Patients aged 18-70 years; (4) Patients diagnosed with qi and yin deficiency and phlegm-heat accumulation in the lungs by traditional Chinese medicine; (5) Patients who have had at least three acute exacerbations in the past year; (6) Patients who are willing to follow the doctor's diagnosis and treatment arrangements and sign the informed consent form.

[0035] 1.2 Exclusion criteria

[0036] (1) Patients who do not meet the above-mentioned Western medical diagnosis and TCM syndrome differentiation criteria, and patients with hemoptysis as the main manifestation of truncal bronchiectasis; (2) Patients whose condition has changed within 4 weeks before enrollment; (3) Pregnant or lactating women; (4) Patients with a history of chronic alcoholism or drug abuse or any factors that affect compliance; (5) Patients with severe primary diseases such as cardiovascular, cerebrovascular, liver, kidney and hematopoietic system, peptic ulcer, etc.; (6) Abnormal liver and kidney function: liver (ALT or AST) exceeds more than one times the upper limit of normal value or renal function (BUN or Cr) is abnormal; (7) Patients with mental illness; (8) Patients with allergic constitution and allergy to this drug; (9) Patients who have participated in other clinical trials within 1 month; (10) Other conditions that the researchers consider unsuitable for inclusion.

[0037] 2. Research Design and Methodology

[0038] Study Design: This study was conducted using the principles of randomized controlled clinical research. Randomization was performed using SPSS 20.0 software. Participants who met the inclusion criteria were randomly divided into two groups: an observation group (Qingbu Weijing Tang granules plus health education plus postural expectoration) and a control group (Carbocisteine ​​oral solution plus health education plus postural expectoration).

[0039] Sample size: Calculated using the number of acute exacerbations as the efficacy evaluation indicator. Literature suggests that carbocysteine ​​can reduce the number of acute exacerbations in patients with airway mucus hypersecretion to 1.01 per year, compared to 1.35 per year in the blank control group (SE = 0.06). This trial employed a superiority design, so the δ value was 0.034. The σ value was 0.06.

[0040] Estimation of test sample: Sample size estimation formula when comparing two sample means (equal number of cases):

[0041]

[0042] (Note: n is the number of sample columns required for each group, σ is the estimated standard deviation, and δ is the allowable error; μα and μβ can be obtained from the μ threshold table. When α = 0.05, the μα value is 1.6 according to the clinical research sample estimation table. When β = 0.2, the μβ value is 0.8 according to the clinical research sample estimation table. σ = 0.06, δ = 0.034) The required sample size is calculated as follows:

[0043]

[0044] Considering a 20% dropout rate for outpatients and a 5% dropout rate for discharged patients, the patient dropout rate is approximately 10% (approximately 4 cases), resulting in a sample size of 40 in the experimental group. Therefore, the total sample size for the observation and control groups is: 40 × 2 = 80 (cases). There are 40 cases in the observation group and 40 cases in the control group.

[0045] 3. Treatment Methods

[0046] 3.1 Control group

[0047] Carbocisteine ​​oral solution (Guangzhou Baiyunshan Pharmaceutical Co., Ltd., national medicine standard number H20073871) 500 mg each time, 3 times a day, orally.

[0048] 3.2 Observation Group

[0049] The Qingbu Weijing Decoction granules prepared in Example 1 were taken as one dose per day, divided into two doses.

[0050] Both groups of patients received health education and postural expectoration.

[0051] 4. Observation items and methods

[0052] Treatment course and follow-up: The treatment course is 12 weeks and the follow-up is 1 year.

[0053] 4.1 Main efficacy indicators

[0054] 1) Number of acute exacerbations: The number of acute exacerbations during medication and follow-up were counted separately.

[0055] 2) CASA-Q Scoring: Scoring was performed using the Cough and Sputum Assessment Questionnaire (CASA-Q) designed by Crawford et al. The CASA-Q includes scores for four domains: cough symptoms (COUS, 3 items), cough impact (COUI, 8 items), sputum symptoms (SPUS, 3 items), and sputum impact (SPUI, 6 items). Scores for the four domains of the CASA-Q were recorded. Changes in CASA-Q domain scores before and after treatment and before and after follow-up were compared within the two groups. Changes in CASA-Q domain scores before and after treatment and before and after follow-up were also compared between the two groups. Scores were recorded once each at enrollment day 0, week 4, week 8, week 12, and at follow-up months 3, 6, 9, and 12, for a total of eight times.

[0056] 4.2 Secondary efficacy indicators

[0057] 1) Symptom quantitative score: recorded once a month, and once every 3 months during the follow-up period.

[0058] 2) Pulmonary function (FEV1, FVC, FEV1 / FVC, PEF value): Measure once before and once after treatment, for a total of 2 times.

[0059] 3) Serum inflammatory markers: blood routine, ESR, CRP, IL-8, IL-10, tumor necrosis factor-α, and neutrophil elastase were tested, once before and after treatment, for a total of 2 times.

[0060] 4) Chest CT modified Reiff score: once before and once after treatment, for a total of 2 times.

[0061] 5. Statistical methods

[0062] Statistical analysis was performed using SPSS 20.0 statistical software. Measurement data that conformed to a normal distribution were analyzed using the t-test and paired t-test; those that did not conform to a normal distribution were analyzed using the rank sum test. Enumeration data were analyzed using the corrected chi-square test. Statistical significance was determined when the P value was less than 0.05.

[0063] 6. Test results

[0064] 6.1 Comparison of the number of acute exacerbations before and after treatment

[0065] 6.1.1 Comparison of the number of acute exacerbations before and after treatment between the two groups: The number of acute exacerbations in the observation group was significantly lower than that in the control group after 12 weeks of treatment, and the comparison between the two groups was statistically significant (P < 0.001); the number of acute exacerbations in the observation group was significantly lower than that in the control group after 1 year of follow-up, and the comparison between the two groups was statistically significant (P < 0.001); the number of acute exacerbations in the observation group was significantly lower than that in the control group after 1 year of follow-up and 1 year before enrollment, and the comparison between the two groups was statistically significant (P < 0.001). (See Table 1)

[0066] Table 1 Comparison of the number of acute exacerbations before and after treatment in the two groups of patients [times, M (P25, P75)]

[0067]

[0068] (Note: The comparison of the number of acute exacerbations between the observation group and the control group after 12 weeks of treatment was P < 0.001 (Z = -4.369, P = 0.000); the comparison of the number of acute exacerbations between the observation group and the control group after 12 months of follow-up was P < 0.001 (Z = -4.903, P = 0.000); the comparison of the number of acute exacerbations between the observation group and the control group during treatment, 12 months of follow-up, and the last 12 months was P < 0.001 (Z = -3.522, P = 0.000).)

[0069] 6.1.2 Comparison of CASA-Q scores before and after treatment (see Table 2)

[0070] Table 2 Comparison of CASA-Q scores before and after treatment between the two groups (points, )

[0071]

[0072] Note: a) Compared with the control group at the same time, P < 0.001; b) Compared with the control group at the same time, P < 0.05; c) Compared with the group before treatment, P < 0.001; d) Compared with the group before treatment, P < 0.05.

[0073] 6.1.3 Comparison of efficacy of TCM symptom scores

[0074] 6.1.3.1 Comparison of symptom score efficacy: (See Table 3 for details)

[0075] Table 3 Comparison of the therapeutic effects of TCM syndromes in the two groups before and after treatment [cases, (%)]

[0076]

[0077] 6.1.3.2 Comparison of total symptom scores: (See Table 4 for details)

[0078] Table 4 Comparison of TCM syndrome scores before and after treatment in the two groups of patients (scores, )

[0079]

[0080] Test Example 2 Anti-inflammatory effect study test

[0081] The case selection method, research design method, treatment method, statistical method, etc. of Experimental Example 2 are the same as those in Example 1. By analyzing the changes in WBC, CRP, ESR, TNF-α, IL-8, IL-10 and neutrophil elastase levels in patients with bronchiectasis before and after treatment, the effect of Qingbu Weijing Decoction Granules on the serum inflammation level of patients with stable bronchiectasis in a state of airway mucus hypersecretion was studied, and the above objective indicators were used to judge its efficacy, and the mechanism of action of Qingbu Weijing Decoction in the treatment of patients with bronchiectasis was explored.

[0082] 1. Research Methods

[0083] This study included 40 patients from each group in the clinical study of Experimental Example 1. Venous blood samples were drawn before and after treatment for testing of white blood cell (WBC), CRP, ESR, and TNF-α levels. Another venous blood sample was centrifuged and serum was collected and stored at -80°C. Neutrophil elastase, IL-8, and IL-10 levels were measured before and after treatment using an enzyme-linked immunosorbent assay (ELISA) using a fully automated multifunctional microplate reader (MULTISKAN MK3, Thermo, USA). Kit information: Human IL10 Elisa kit, manufacturer: NOVUS, catalog number: VAL112, batch number: 274141; Human IL8 ELISA kit, manufacturer: RD, catalog number: D8000C, batch number: P240098; Neutrophil elastase ELISA kit, manufacturer: RD, catalog number: DY9167-05, batch number: P231697.

[0084] The changes of serum WBC, CRP, ESR, TNF-α, NE, IL-8 and IL-10 before and after treatment were compared between the two groups of patients, and statistical analysis was performed.

[0085] Statistical methods: SPSS 20.0 statistical software was used for statistical analysis, using t-test, paired t-test, rank sum test, and paired rank sum test. Statistical significance was determined when the P value was less than 0.05.

[0086] 2. Comparison of serum inflammatory factor levels between the two groups of patients before and after treatment: (Table 5)

[0087] Table 5 Comparison of serum inflammatory markers (CRP, TNF-α, IL-8, IL-10, NE) levels before and after treatment in the two groups (M(Q1, Q3))

[0088]

[0089] Note: a) Compared with the control group at the same time, the difference was P < 0.001; b) Compared with the control group at the same time, the difference was P < 0.05; c) Compared with the group before treatment, the difference was P < 0.001; d) Compared with the group before treatment, the difference was P < 0.05.

[0090] The above clinical trials found that Qingbu Weijing Decoction has a trend of downregulating the levels of WBC, CRP, ESR, TNF-α, IL-8, IL-10, and NE, among which the improvements in IL-8, IL-10, and NE were statistically significant; compared with the control group, there was a statistically significant decrease in IL-8 in the observation group before and after treatment.

[0091] The above experimental data show that Qingbu Weijing Tang granules can significantly reduce the number of acute exacerbations in patients with bronchiectasis in the stable stage of airway mucus hypersecretion; improve patients' TCM syndromes and cough, sputum symptoms and adverse effect scores, thereby improving patients' quality of life; at the same time, it can partially improve the patient's lung function, and at the same time, there is a trend of reducing the serum inflammatory factors and protease levels of bronchiectasis patients; no obvious adverse reactions were found. Thus, it is confirmed that the Chinese medicine composition provided by the present invention is an effective TCM treatment for patients with bronchiectasis in the state of airway mucus hypersecretion (Qi Yin deficiency, phlegm heat in the lungs), can improve cough and sputum symptoms, and reduce multiple inflammatory factors to a certain extent, and has obvious clinical efficacy in treating bronchiectasis with phlegm heat in the lungs and Qi Yin deficiency type airway mucus hypersecretion.

[0092] Those skilled in the art will appreciate that the above-mentioned embodiments are specific examples for implementing the present invention, and that in actual applications, various changes may be made thereto in form and detail without departing from the spirit and scope of the present invention.

Claims

1. A Chinese medicine composition for treating bronchiectasis, characterized in that: The medicine is prepared from the following Chinese medicinal raw materials in parts by weight: 30 parts of reed rhizome, 30 parts of raw astragalus, 10 parts of codonopsis pilosula, 20 parts of ophiopogon, 10 parts of roasted licorice, 20 parts of raw coix seed, 15 parts of wax gourd seed, 10 parts of peach kernel, 10 parts of pinellia, 12 parts of platycodon, 15 parts of aster, and 10 parts of polygala.

2. A method for preparing a Chinese medicine composition for treating bronchiectasis, characterized in that: The steps include: (1) Weigh the following Chinese medicinal materials in parts by weight: 30 parts of Phragmites australis, 30 parts of raw Astragalus root, 10 parts of Codonopsis pilosula, 20 parts of Radix Ophiopogonis, 10 parts of Radix Glycyrrhizae, 20 parts of raw Coix seeds, 15 parts of Wax gourd seeds, 10 parts of Peach kernel, 10 parts of Pinellia tuber, 12 parts of Platycodon grandiflorum, 15 parts of Aster tataricus, and 10 parts of Polygala tenuifolia. (2) After mixing the Chinese medicinal raw materials, extracting them with a solvent, obtaining an extract, and further preparing the extract into a desired dosage form; in the solvent extraction, the extraction method is water decoction extraction or alcohol solution extraction.

3. The preparation method according to claim 2, characterized in that In the step of preparing the desired dosage form, the traditional Chinese medicine composition is prepared into a conventional dosage form using a conventional traditional Chinese medicine preparation method.

4. The preparation method according to claim 2, characterized in that The traditional Chinese medicine composition is prepared into granules, decoctions, tablets, capsules or pills.

Images